A novel PEGylated interferon beta-1a for multiple sclerosis: safety, pharmacology, and biology. (Q53151534)

11 May 2018

title

A novel PEGylated interferon beta-1a for multiple sclerosis: safety, pharmacology, and biology. (English)

1 reference

11 May 2018

0 references

1 reference

1 reference

Xiao Hu

1

1 reference

11 May 2018

Larisa Miller

2

1 reference

11 May 2018

Sandra Richman

3

1 reference

11 May 2018

Stacy Hitchman

4

1 reference

11 May 2018

Gabrielle Glick

5

1 reference

11 May 2018

Shifang Liu

6

1 reference

11 May 2018

Ying Zhu

7

1 reference

11 May 2018

Mary Crossman

8

1 reference

11 May 2018

Ivan Nestorov

9

1 reference

11 May 2018

Robert S Gronke

10

1 reference

11 May 2018

Darren P Baker

11

1 reference

11 May 2018

Mark Rogge

12

1 reference

11 May 2018

Meena Subramanyam

13

1 reference

11 May 2018

Gudarz Davar

14

1 reference

11 May 2018

publication date

16 June 2011

1 reference

11 May 2018

The Journal of Clinical Pharmacology

published in

1 reference

11 May 2018

volume

52

1 reference

11 May 2018

issue

6

1 reference

11 May 2018

page(s)

798-808

1 reference

11 May 2018

Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG)

cites work

1 reference

https://api.crossref.org/works/10.1177%2F0091270011407068

Switching algorithms: from one immunomodulatory agent to another

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270011407068

Injectable medication for the treatment of multiple sclerosis: the influence of self-efficacy expectations and injection anxiety on adherence and ability to self-inject

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270011407068

Addressing the need for increased adherence to multiple sclerosis therapy: can delivery technology enhance patient motivation?

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270011407068

The impact of PEGylation on biological therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270011407068

PEGylation: an approach for drug delivery. A review

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270011407068

N-terminally PEGylated human interferon-beta-1a with improved pharmacokinetic properties and in vivo efficacy in a melanoma angiogenesis model.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270011407068

PEGylated Interferon Beta-1a: Meeting an Unmet Medical Need in the Treatment of Relapsing Multiple Sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270011407068

Beta-2 microglobulin and neopterin as markers of disease activity in multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270011407068

Influence of interferon beta-1a dose frequency on PBMC cytokine secretion and biological effect markers

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270011407068

Pharmacokinetics and pharmacodynamics of the interferon-betas, glatiramer acetate, and mitoxantrone in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270011407068

Reciprocal modulation between TH17 and other helper T cell lineages

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270011407068

B-cell depletion with rituximab in relapsing-remitting multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270011407068

Recommendations for clinical use of data on neutralising antibodies to interferon-beta therapy in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270011407068

Neutralising antibodies to interferon beta in multiple sclerosis : expert panel report

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270011407068

Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270011407068

21 January 2018

Identifiers

DOI

10.1177/0091270011407068

1 reference

11 May 2018

1 reference

11 May 2018